Gynecologic Cancers

Latest News

Cervical Cancer
Cadonilimab/Chemotherapy Meets Primary End Point in Phase 3 AK104-303 Trial

December 3rd 2023

Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.

gynecologic cancer
Why a Trauma-Informed Approach Is Ideal in Gynecologic Cancer Care

November 29th 2023

ovarian cancer
Olaparib Misses Mark in Recurrent Platinum-Sensitive Ovarian Cancer

November 25th 2023

Endometrial Cancer
Patients With Endometrial Cancer Report Maintained HRQOL With Dostarlimab

November 21st 2023

New Management Strategies Seek to Improve Quality of Life for Patients With Lymphedema

November 20th 2023

Latest CME Events & Activities

2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition

December 8, 2023

Register Now!

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2023 MJH Life Sciences

All rights reserved.